Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JIN-A02 + Amivantamab in EGFR-Mutant NSCLC After 3rd-Gen EGFR-TKI Failure
NCT07798921Phase 1Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Sep 2026
- Primary completion
- Jun 2028
01
Overview
Phase 1, open-label, single-arm trial of JIN-A02 in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose of JIN-A02 in Combination With Amivantamab at 8 months and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
JIN-A02
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07798921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07798921.